Double Bond Pharmaceutical International
0.14 SEK
+10.85 %
Less than 1K followers
DBP B
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+10.85 %
+7.52 %
+17.21 %
+20.17 %
+38.83 %
-52.09 %
-75.74 %
-88.15 %
-95.10 %
Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.
Read moreMarket cap
30.65M SEK
Turnover
7.06K SEK
Revenue
84.22K
EBIT %
-2,006.39 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22/5
2026
Interim report Q1'26
27/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
DBP: Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed
DBP: Kommuniké från årsstämma den 23 april 2026 i Double Bond Pharmaceutical International AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools